PERSON DIRECTORY
Martin Shkreli
Martin Shkreli appears in 2 indexed conversations across All-In, Gradient Dissent. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.
Martin Shkreli: Big Pharma's Blind Spot, Betting Against Quantum & What Prison Taught Him
Shkreli limits quantum’s edge to factoring and elliptic-curve logarithms; current machines lack quantum RAM.He calls industry spending speculative and expects analog optical computing to challenge Nvidia’s H100, B100, and B200 within 20 years.His pharmaceutical thesis favors mispriced discarded molecules; he calls AI drug discovery within five years “nonsense” and expects no AI-related drug in the next 10 years.
From pharma to AGI hype, and developing AI in finance: Martin Shkreli’s journey
AI’s largest biopharma opportunity may be target selection rather than molecule generation, with an LLM reading roughly 36-38 million PubMed papers to identify overlooked clinical opportunities.BTK illustrates the mechanism: valuable research sat published for 15-20 years, while clinical trials still consume 50-70% of total cost and development cycles approach ten years.Shkreli’s finance suite found millions of dollars in revenue after abandoning forced AI positioning, but breaking-news advantages may diffuse across Wall Street within six months to a year.